Kamada (KMDA) closed the last trading session at $6.85, gaining 2.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $14.17 indicates a 106.9% upside potential.The mean estimate comprises six short-term price targets with a standard deviation of $3.13. While the lowest estimate of $11 indicates a 60.6% increase from the current price level, the most optimistic analyst expects the s ...

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Kamada (KMDA) or CSL Limited Sponsored ADR (CSLLY) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks Ran ...

Kamada (KMDA) Q1 2025 Earnings Call May 14, 2025 08:30 AM ET Company Participants Brian Ritchie - Managing DirectorAmir London - Chief Executive OfficerChaime Orlev - Chief Financial OfficerAnnabel Samimy - Managing Director Conference Call Participants Jim Sidoti - Analyst Operator Greetings, and welcome to the Comida First Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. As a re ...

Kamada (KMDA) Q1 2025 Earnings Call May 14, 2025 08:30 AM ET Company Participants Brian Ritchie - Managing DirectorAmir London - Chief Executive OfficerChaime Orlev - Chief Financial OfficerAnnabel Samimy - Managing Director Conference Call Participants Jim Sidoti - Analyst Operator Greetings, and welcome to the Comida First Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. As a re ...

Financial Data and Key Metrics Changes - Total revenues for Q1 2025 were $44 million, representing a 17% increase year over year from $37.7 million in Q1 2024 [4][11] - Adjusted EBITDA for Q1 2025 was $11.6 million, a 54% increase compared to $7.5 million in Q1 2024 [4][13] - Net income for Q1 2025 was $4 million, or $0.07 per share, up 67% from $2.4 million, or $0.04 per share, in Q1 2024 [13] Business Line Data and Key Metrics Changes - Growth was primarily driven by increased sales of Glacia and Kamrab in ex-U.S. markets, as well as Varezig sales and Glacier royalties income [5][11] - Gross profit for Q1 2025 was $20.7 million with a gross margin of 47%, compared to $16.7 million and 44% in Q1 2024 [12] Market Data and Key Metrics Changes - The company expects to launch two additional biosimilars later in 2025, following the first biosimilar product launch in Israel, which is projected to generate approximately $2 million in revenue this year [8] - The plasma collection operation expanded with a new center in San Antonio, Texas, expected to contribute annual revenues of $8 million to $10 million [9][10] Company Strategy and Development Direction - The company is focused on a four-pillar growth strategy: organic commercial growth, business development and M&A, plasma collection operations, and advancement of the inhaled Alpha-one program [6][39] - A comprehensive post-marketing research program for Cytogam was initiated, consisting of 10 studies aimed at advancing CMV disease management [6][7] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about continued profitable growth throughout 2025, reiterating annual revenue guidance of $178 million to $182 million and adjusted EBITDA guidance of $38 million to $42 million [5][6] - The company is monitoring the impact of tariffs and NIH spending cuts but does not anticipate a direct impact on its business [21][31] Other Important Information - The company is currently at around 55% enrollment for the pivotal Phase III INNO2VATE clinical trial for inhaled alpha-one antitrypsin therapy [26] - The tax rate reported for the quarter was 40%, compared to 3% a year ago, with expectations of fluctuations in tax expenses through 2025 [33][34] Q&A Session Summary Question: Growth contributors and Cytogam investment - Management clarified that Cytogam did not significantly contribute to growth this quarter, with the increase coming from other products [15][18] Question: Updates on CMV guidelines - Management indicated that new clinical data from ongoing studies could lead to updates in CMV management guidelines [19][20] Question: Impact of tariffs on global business - Management stated that there should be no direct impact on sales from tariffs, but they will continue to monitor the situation [21][24] Question: Timing of Cytogam post-marketing study completion - The comprehensive program is expected to span around four years, with some results available as early as late 2025 [30] Question: Impact of NIH spending cuts - Management does not anticipate any impact from NIH spending cuts on the business [31] Question: Tax rate changes - The tax rate change was due to shifts between deferred tax assets and liabilities, with expectations of a clearer effective tax rate by the end of 2025 [33][34] Question: Annual guidance implications from strong Q1 - Management will monitor progress in Q2 and may update guidance if strong performance continues [37]

Kamada (KMDA) came out with quarterly earnings of $0.07 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.04 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this biopharmaceutical would post earnings of $0.05 per share when it actually produced earnings of $0.07, delivering a surprise of 40%.Over the last four quarters, the company has surpassed consensus EPS estimates two times.Kamada, which belongs to the Zack ...

Core Viewpoint - Kamada Ltd. has received a tax ruling from the Israel Tax Authority regarding a special cash dividend of $0.20 per share, totaling approximately $11.5 million, which is set to be paid on April 7, 2025, to shareholders of record as of March 17, 2025 [1][2]. Tax Ruling and Dividend Distribution - The ruling allows Nasdaq Shareholders from countries with a tax treaty with Israel to potentially benefit from a reduced withholding tax rate on the dividend [2][7]. - Nasdaq Shareholders who are Israeli corporate shareholders may qualify for an exemption from Israeli withholding tax under the ruling [2][12]. - The company will withhold 25% of the dividend amount on the payment date and remit it to the Tax Agent, with the remaining 75% distributed to shareholders [8][13]. Documentation and Compliance - Nasdaq Shareholders must submit required forms to the Tax Agent to benefit from the reduced withholding tax rate, with a deadline of May 5, 2025 [5][17]. - Specific documentation is required for shareholders declaring residency in a Treaty State, including bank account details and proof of residency [9][10]. - Non-Israeli corporate shareholders must provide additional documentation, such as a register of shareholders or partners as of the record date [11]. Company Overview - Kamada Ltd. is a global biopharmaceutical company focused on rare and serious conditions, with a portfolio of FDA-approved specialty plasma-derived products [19]. - The company's growth strategy includes organic growth, business development, expansion of plasma collection operations, and advancing product candidates in clinical trials [19].

Financial Data and Key Metrics Changes - Total revenue for 2024 was $161 million, a 13% increase from $143 million in 2023, meeting the annual guidance [22][8] - Adjusted EBITDA reached a record $34.1 million, representing a 42% year-over-year growth from $24.1 million in 2023 [27][8] - Net income for 2024 was $14.5 million, or $0.25 per diluted share, up 75% from $8.3 million, or $0.15 per diluted share in 2023 [26][22] - Cash generated from operations was $47.6 million, with a year-end cash balance of $78.4 million [9][8] Business Line Data and Key Metrics Changes - KEDRAB sales contributed $50 million in total sales during 2024, with a minimum commitment from Kedrion of $135 million for the remaining three years of the agreement [23][22] - CYTOGAM sales were $23 million, up 31% compared to 2023 [24][22] - Gross profit for 2024 was $70 million, with gross margins improving to 43% from 39% in 2023 [24][22] Market Data and Key Metrics Changes - The company expanded its presence in the MENA region and secured a three-year contract for KAMRAB and VARIZIG in Latin America, expected to generate approximately $25 million in revenue [14][15] - The company launched its first biosimilar product in Israel in 2024, with plans for two additional launches in 2025 [15][12] Company Strategy and Development Direction - The growth strategy focuses on organic growth, business development and M&A, expansion of plasma collection operations, and advancing the inhaled AAT product trial [12][10] - The company aims to continue delivering double-digit profitable growth in 2025, with forecasted revenues of $178 million to $182 million [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's business prospects, citing strong financial results and a favorable outlook for 2025 [10][9] - The company is well-positioned to execute on its growth strategy with ample liquidity and a solid cash position [9][10] Other Important Information - A special cash dividend of $0.20 per share was declared, reflecting the company's strong financial performance and commitment to shareholder value [9][10] - The company opened a second plasma collection center in Houston and is set to open a third center in San Antonio, expected to contribute $8 million to $10 million in annual revenues each [18][17] Q&A Session Summary Question: Inquiry about the futility analysis for the inhaled AAT program - Management confirmed that the futility analysis will be blinded and conducted by an external group, focusing on conditional efficacy data [33][34] Question: Additional growth drivers for KEDRAB and CYTOGAM - Management indicated that KEDRAB's growth is driven by international expansion, while CYTOGAM will see advancements in clinical work and presentations at medical conferences [46][52] Question: Reason for declaring a special dividend - The decision was based on strong financial results and a solid cash position, allowing the company to pay dividends while pursuing business development activities [53][54] Question: Details on the third plasma collection center - The San Antonio center is expected to reach peak revenue in 24 to 30 months, collecting both specialty and normal source plasma [62][63] Question: Impact of internal plasma collection on gross margins - Management noted that using internally collected plasma will improve cost efficiencies, but it will take time to replace purchased plasma with collected plasma [82][83]

Kamada Ltd. (NASDAQ:KMDA) Q4 2024 Earnings Conference Call March 5, 2025 8:00 AM ET Company Participants Brian Ritchie – LifeSci Advisors Amir London – Chief Executive Officer Chaime Orlev – Chief Financial Officer Conference Call Participants Annabel Samimy – Stifel Anthony Petrone – Mizuho Group James Sidoti – Sidoti & Co. Operator Greetings, and welcome to the Kamada Fourth Quarter and Full Year 2024 Earnings Conference Call. At this time all participants are in a listen-only mode. A brief question-and-a ...

Financial Projections - The company expects total revenues for fiscal year 2025 to be in the range of $178 million to $182 million, representing a year-over-year increase of 12%[22]. - Adjusted EBITDA for fiscal year 2025 is projected to be between $38 million and $42 million, indicating a 17% increase year-over-year[22]. - A special cash dividend of $0.20 per share, totaling approximately $11.5 million, is planned for April 7, 2025[22]. - The company anticipates receiving royalties from Takeda in the range of $10 million to $20 million per year from 2025 to 2040 based on GLASSIA sales[22]. - The company has a commitment from Kedrion Biopharma Inc. to purchase minimum quantities of KEDRAB, generating approximately $180 million in revenue from 2024 to 2027[24]. Revenue Sources - Revenue from Proprietary Products comprised approximately 88%, 81%, and 79% of total revenues for the years ended December 31, 2024, 2023, and 2022, respectively[44]. - Sales of KEDRAB, CYTOGAM, and royalty income from GLASSIA accounted for approximately 31%, 14%, and 10% of total revenues for the year ended December 31, 2024, totaling 55%[42]. - A significant portion of net revenue, approximately 62%, 52%, and 50% for the years ended December 31, 2024, 2023, and 2022, respectively, was generated in the United States[45]. - Sales to Kedrion accounted for approximately 31%, 23%, and 13% of total revenues for the years ended December 31, 2024, 2023, and 2022, respectively, with projected minimum aggregate revenues of approximately $180 million over the four-year period from 2024 to 2027[54]. Product Development and Clinical Trials - The InnovAATe clinical trial for Inhaled AAT is ongoing, with recruitment expected to be completed by the end of 2026 and treatment for the last patient by the end of 2028[26]. - The company is engaged in the InnovAATe clinical trial for its lead investigational product, Inhaled AAT for AATD, with a planned reduction in study sample size from 220 to approximately 180 patients[51]. - The Phase 2/3 clinical trial for Inhaled AAT for AATD did not meet its primary or secondary endpoints, leading to the withdrawal of the Marketing Authorization Application in Europe[133]. - The company plans to conduct an interim futility analysis for the InnovAATe clinical study by the end of 2025, which could impact business prospects[147]. Plasma Collection Operations - The Houston and San Antonio plasma collection centers are expected to contribute annual revenues of $8 million to $10 million each from normal source plasma sales once fully operational[24]. - The company plans to expand its plasma collection operations, with a third center in San Antonio expected to commence operations by the end of Q1 2025[24]. - The company owns an FDA-licensed plasma collection center in Beaumont, Texas, and has opened a new plasma collection center in Houston, Texas, expected to be one of the largest in the U.S.[48]. - The company has expanded its plasma collection operations with a new center in Houston, Texas, expected to be one of the largest hyper-immune plasma collection sites in the U.S.[98]. - The company is in advanced stages of constructing a third plasma collection site in San Antonio, Texas, anticipated to open by the end of Q1 2025[98]. Market and Competitive Landscape - Future growth is dependent on the ability to maintain and expand sales of commercial products in the U.S. and international markets[41]. - The Proprietary Products segment faces competition from large biopharmaceutical companies, including CSL Behring and Takeda, which have significant advantages in market resources and experience[67]. - The company’s products do not benefit from patent protection, leading to potential revenue reductions due to competition from similar products[73]. - The company may face significant risks in product development due to potential obstacles such as supply shortages, clinical trial failures, and regulatory approval delays[154]. Regulatory and Compliance Challenges - Regulatory compliance is critical, as noncompliance could lead to significant inventory impairment provisions and write-offs, adversely affecting financial results[100]. - The company is subject to evolving regulatory requirements, which could increase compliance costs and impact profit margins[108]. - The company must comply with comprehensive privacy and security standards, with non-compliance potentially leading to litigation and significant costs[176]. - Noncompliance with healthcare fraud laws could lead to severe penalties, including exclusion from federal healthcare programs[197]. Risks and Uncertainties - The company may face operational, technical, and regulatory challenges in establishing and maintaining plasma collection operations, which could affect its investment returns[50]. - The company faces risks related to donor availability, which can be impacted by factors such as reimbursement rates and competition, potentially leading to decreased plasma supply[91]. - The company may not be able to successfully build a commercial organization or program, which is critical for transitioning from research to market[150]. - The company may seek partnerships or joint ventures to augment its product pipeline, facing risks if third parties fail to meet obligations[156]. Pricing and Reimbursement - The company’s pricing and reimbursement depend on government regulations, with potential impacts from healthcare system reforms[205]. - The company may be adversely affected by government or private third-party payors limiting reimbursement amounts for its products[203]. - The company must conduct clinical trials for reimbursement approval in some countries, which can be time-consuming and expensive[204]. Intellectual Property and Patent Issues - The patent landscape in biotechnology and pharmaceuticals is highly complicated and uncertain, involving complex legal, factual, and scientific questions[218]. - Changes in patent laws or their interpretation may diminish the value and strength of the company's intellectual property[218]. - The company may fail to apply for or be unable to obtain necessary patents to protect its technology or products[218]. - Many patents relate to processes used to produce products rather than the products themselves, which may not be patentable[218].